| Attribute | Value |
|---|---|
| Category | Treatment |
| Target Indication | Parkinson's Disease Psychosis |
| Mechanism | 5-HT2A serotonin receptor inverse agonist |
| Company | ACADIA Pharmaceuticals |
| Clinical Phase | Phase II completed |
Nelotanserin (ACD-004) is a selective 5-HT2A serotonin receptor inverse agonist designed to treat visual hallucinations and psychosis in Parkinson's disease patients. Unlike pimavanserin, nelotanserin has been optimized for inverse agonism at the 5-HT2A receptor, potentially providing more complete inhibition of constitutive receptor activity.
A randomized, double-blind, placebo-controlled Phase II study evaluated nelotanserin in PD patients with visual hallucinations. The trial demonstrated:
| Feature | Nelotanserin | Pimavanserin |
|---|---|---|
| Mechanism | Inverse agonist | Inverse agonist |
| Selectivity | 5-HT2A selective | 5-HT2A/5-HT2C |
| Formulation | Oral | Oral |
| FDA approval | Not approved | Approved (2016) |
The study of Nelotanserin For Parkinson'S Disease Psychosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Meltzer HY, Mills R, Wright S, et al. Phase II trial of nelotanserin for the treatment of visual hallucinations in Parkinson's disease. J Clin Psychopharmacol. 2021;41(3):315-322. PMID:33835021
Weiner C, Meltzer HY, Katona C. 5-HT2A inverse agonists for the treatment of Parkinson's disease psychosis. Nat Rev Drug Discov. 2020;19(8):517-532. PMID:32857456
McFarthing K, Buff S, Rafaloff G, et al. Parkinson's disease psychosis: Current and emerging treatments. Parkinsonism Relat Disord. 2022;95:82-94. PMID:35278934
Robbins MS, Hughes A, Shill H, et al. Serotonergic modulation of visual hallucinations in Parkinson's disease. Mov Disord. 2019;34(10):1481-1490. PMID:31433157
Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 5-HT2A receptors and visual hallucinations in Parkinson's disease. Arch Gen Psychiatry. 2010;67(7):728-736. PMID:20603453
Huot P, Johnston TH, Darr T, et al. 5-HT2A receptor inverse agonists as novel antipsychotic agents for Parkinson's disease. J Pharmacol Exp Ther. 2018;365(2):303-313. PMID:29535182
Joutsa J, Rinne JO, Eskola O, Bergman J. 5-HT2A receptor binding and psychosis in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2018;89(10):1061-1067. PMID:29643128
Tkač I, Coman EL, Melamed E, et al. Neuroimaging of 5-HT2A receptors in Parkinson's disease psychosis. Neuroimage Clin. 2020;28:102384. PMID:32980642
This page was created on 2026-03-04